Recent developments in the assessment of efficacy in clinical trials of diabetic neuropathy

Moaz Mojaddidi; Cristian Quattrini; Mitra Tavakoli; Rayaz A. Malik

doi:10.1007/s11892-005-0048-6

Recent developments in the assessment of efficacy in clinical trials of diabetic neuropathy

Moaz Mojaddidi, Cristian Quattrini, Mitra Tavakoli, Rayaz A. Malik

Research output: Contribution to journal › Article › peer-review

Abstract

A large number of measures may be employed in clinical practice and for epidemiologic studies to quantify and risk stratify diabetic patients with neuropathy. However, not all measures are suitable for assessing the benefits of therapeutic intervention. Therefore, for the purpose of this review we focus on measures that may be employed to define the efficacy of interventions in clinical trials of human diabetic neuropathy. Two major types of end points are used: 1) those that assess symptoms for defining efficacy in painful diabetic neuropathy, and 2) those that assess neurologic deficits that assess the effects of treatments that may prevent further degeneration or promote repair. Copyright © 2005 by Current Science Inc.

Original language	English
Pages (from-to)	417-422
Number of pages	5
Journal	Current Diabetes Reports
Volume	5
Issue number	6
DOIs	https://doi.org/10.1007/s11892-005-0048-6
Publication status	Published - Dec 2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11892-005-0048-6

Cite this

@article{31ace29f99be4ac18ee6a4a3a75173bc,

title = "Recent developments in the assessment of efficacy in clinical trials of diabetic neuropathy",

abstract = "A large number of measures may be employed in clinical practice and for epidemiologic studies to quantify and risk stratify diabetic patients with neuropathy. However, not all measures are suitable for assessing the benefits of therapeutic intervention. Therefore, for the purpose of this review we focus on measures that may be employed to define the efficacy of interventions in clinical trials of human diabetic neuropathy. Two major types of end points are used: 1) those that assess symptoms for defining efficacy in painful diabetic neuropathy, and 2) those that assess neurologic deficits that assess the effects of treatments that may prevent further degeneration or promote repair. Copyright {\textcopyright} 2005 by Current Science Inc.",

author = "Moaz Mojaddidi and Cristian Quattrini and Mitra Tavakoli and Malik, {Rayaz A.}",

year = "2005",

month = dec,

doi = "10.1007/s11892-005-0048-6",

language = "English",

volume = "5",

pages = "417--422",

journal = "Current Diabetes Reports",

issn = "1534-4827",

publisher = "Current Medicine Group",

number = "6",

}

TY - JOUR

T1 - Recent developments in the assessment of efficacy in clinical trials of diabetic neuropathy

AU - Mojaddidi, Moaz

AU - Quattrini, Cristian

AU - Tavakoli, Mitra

AU - Malik, Rayaz A.

PY - 2005/12

Y1 - 2005/12

N2 - A large number of measures may be employed in clinical practice and for epidemiologic studies to quantify and risk stratify diabetic patients with neuropathy. However, not all measures are suitable for assessing the benefits of therapeutic intervention. Therefore, for the purpose of this review we focus on measures that may be employed to define the efficacy of interventions in clinical trials of human diabetic neuropathy. Two major types of end points are used: 1) those that assess symptoms for defining efficacy in painful diabetic neuropathy, and 2) those that assess neurologic deficits that assess the effects of treatments that may prevent further degeneration or promote repair. Copyright © 2005 by Current Science Inc.

AB - A large number of measures may be employed in clinical practice and for epidemiologic studies to quantify and risk stratify diabetic patients with neuropathy. However, not all measures are suitable for assessing the benefits of therapeutic intervention. Therefore, for the purpose of this review we focus on measures that may be employed to define the efficacy of interventions in clinical trials of human diabetic neuropathy. Two major types of end points are used: 1) those that assess symptoms for defining efficacy in painful diabetic neuropathy, and 2) those that assess neurologic deficits that assess the effects of treatments that may prevent further degeneration or promote repair. Copyright © 2005 by Current Science Inc.

U2 - 10.1007/s11892-005-0048-6

DO - 10.1007/s11892-005-0048-6

M3 - Article

C2 - 16316591

SN - 1534-4827

VL - 5

SP - 417

EP - 422

JO - Current Diabetes Reports

JF - Current Diabetes Reports

IS - 6

ER -

Recent developments in the assessment of efficacy in clinical trials of diabetic neuropathy

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this